|
Sargramostim
resources
|
|
|
|
|
|
DRUG INFO
Sargramostim
Drug Name:
Sargramostim
Indication: Increases leukocyte production, for treatment in cancer and bone marrow transplant
Pharmacology: Used in the treatment of bone marrow transplant recipients or those exposed to chemotherapy an recovering from acut myelogenous leukemia, Leukine or GM-CSF is a hematopoietic growth factor which stimulates the survival, clonal expansion (proliferation) and differentiation of hematopoietic progenitor cells. GM-CSF is also capable of activating mature granulocytes and macrophages. After a bone marrow transplant or chemotherapy, patients have a reduced capacity to produce red and white blood cells. Supplementing them with external sources of GM-CSF helps bring the level of neutrophils back to normal so that they can better fight infections.
Mechanism Of Action: Leukine binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of hemopoietic cells and neutrophils
Drug Category: Immunomodulatory Agents; Antineoplastic Agents; Anti-infective Agents
Brand Names/Synonyms: Granulocyte-macrophage colony-stimulating factor precursor;GM-CSF;Colony-stimulating factor;CSF;Sargramostim;Molgramostin; Leukine (Berlex Laboratories Inc; Immunex); Leucomax (Novartis)
Dosage Forms: Not Available
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Human granulocyte macrophage colony stimulating factor
Chemical Formula: C639H1006N168O196S8
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: BIOD00035
CAS Registry Number: 83869-56-1
|
|
|
|
|
|
Sargramostim News
(When available)
Berlex Oncology Introduces New Formulation of Leukine(R) With ... Jan 10, 2006
PR Newswire (press release), Berlex Laboratories, a US affiliate of Schering AG, Germany (NYSE: SHR, FSE: SCH), today announced its granulocyte macrophage colony stimulating factor (GM-CSF ...
Rituxan® Plus GM-CSF Safe and Effective for Chronic Lymphocytic ... Jan 13, 2006
Cancer Consultants (press release), Anderson Cancer Center have reported that the combination of Rituxan® (rituximab) and granulocyte macrophage-colony stimulating factor (Leukine®, sargramostim ...
Rituxan® Plus GM-CSF Safe and Effective for Chronic Lymphocytic ... Jan 12, 2006
Cancer Consultants (press release), Anderson Cancer Center have reported that the combination of Rituxan (rituximab) and granulocyte macrophage-colony stimulating factor, Leukine®, (sargramostim ...
New preparation Leucostim been developed for treatment of ... Jan 9, 2006
I-Newswire.com (press release) ...biotech company Biocad has successfully completed a multicenter comparative clinical trial of the first domestic granulocyte colony stimulating factor Leucostim ...
Berlex Oncology Introduces New Formulation of Leukine with ... Jan 10, 2006
DG News Oncology, a unit of Berlex Laboratories, a US affiliate of Schering AG, Germany, today announced its granulocyte macrophage colony stimulating factor (GM-CSF ...
Chemokine Therapeutics to present phase 1 clinical data at the ... Jan 9, 2006
Canada NewsWire (press release), ...and pharmacokinetic profile of CTCE-0214 as a single injection, multi-dose, and in combination with granulocyte colony stimulating factor (G-CSF). ...
BiovaxID, Personalized Anti-Cancer Vaccine from Biovest ... Jan 10, 2006
PharmaLive.com (press release), ...of tumor-derived Id protein (tumor antigen) conjugated to KLH as a carrier protein administered with GM-CSF (granulocyte macrophage colony stimulating factor). ...
Neose Technologies to Present at JPMorgan Healthcare Conference Jan 5, 2006
PharmaLive.com (press release), ...are NE- 180 (GlycoPEG-EPO), a long-acting version of erythropoietin, and GlycoPEG- GCSF, a long-acting version of granulocyte colony stimulating factor (G-CSF ...
‘Transfusion not necessary’ Dec 18, 2005
Trinidad News, Among the other alternatives to blood transfusions are G-CSF (granulocyte colony stimulating factor) and GM-CSF (granulocyte macrophage colony stimulating ...
Zenotech to launch two bio generics in Feb, plans GDR Dec 20, 2005
Newindpress, The two products - recombinant human granulocyte macrophage-colony stimulating factor (GM-CSF) and recombinant human granulocyte colony stimulating factor (G ...
REACTIVE ARTHRITIS DUE TO PREVIOUS INFECTION Dec 20, 2005
Charlotte Sun-Herald, Felty's too. Granulocyte colony-stimulating factor is another treatment. Granulocyte is a synonym for white blood cells. Without ...
Taxane-Based Breast Cancer Treatment Cost-Effective Compared to 5 ... Dec 13, 2005
DG News ..."Most clinicians, in order to prevent bouts of febrile neutropenia would add GM-CSF [granulocyte monocyte colony stimulating factor]," she said. ...
Rituxan® Plus GM-CSF Safe and Effective for Chronic Lymphocytic ... Jan 13, 2006
Cancer Consultants (press release), Reference: Ferrajoli A, O’Brien SM, Faderl SH et al. Rituximab plus GM-CSF for Patients with Chronic Lymphocytic Leukemia. Blood. ...
Rituxan® Plus GM-CSF Safe and Effective for Chronic Lymphocytic ... Jan 12, 2006
Cancer Consultants (press release), Reference: Ferrajoli A, O’Brien SM, Faderl SH, et al. Rituximab plus GM-CSF for patients with chronic lymphocytic leukemia. Blood . ...
Berlex Oncology Introduces New Formulation of Leukine With ... Jan 10, 2006
PharmaLive.com (press release), ...a unit of Berlex Laboratories, a US affiliate of Schering AG, Germany , today announced its granulocyte macrophage colony stimulating factor (GM-CSF) LEUKINE(R ...
Berlex Oncology Introduces New Formulation of Leukine(R) With ... Jan 10, 2006
PR Newswire (press release), Laboratories, a US affiliate of Schering AG, Germany (NYSE: SHR) , today announced its granulocyte macrophage colony stimulating factor (GM-CSF) LEUKINE(R ...
BiovaxID, Personalized Anti-Cancer Vaccine from Biovest ... Jan 10, 2006
PharmaLive.com (press release), BiovaxID is comprised of tumor-derived Id protein (tumor antigen) conjugated to KLH as a carrier protein administered with GM-CSF (granulocyte macrophage ...
Berlex Oncology Introduces New Formulation of Leukine(R) With ... Jan 10, 2006
PR Newswire (press release), ...a US affiliate of Schering AG, Germany (NYSE: SHR, FSE: SCH), today announced its granulocyte macrophage colony stimulating factor (GM-CSF) LEUKINE(R ...
Zenotech to launch two bio generics in Feb, plans GDR Dec 20, 2005
Newindpress, The two products - recombinant human granulocyte macrophage-colony stimulating factor (GM-CSF) and recombinant human granulocyte colony stimulating factor (G ...
‘Transfusion not necessary’ Dec 18, 2005
Trinidad News, Among the other alternatives to blood transfusions are G-CSF (granulocyte colony stimulating factor) and GM-CSF (granulocyte macrophage colony stimulating ...
Synta Pharmaceuticals to Focus 2006 Development on Its Oral IL-12 ... Dec 23, 2005
Yahoo! News (press release) ...of pro-inflammatory Th1 cytokines active in psoriasis, such as IL-23, and increased levels of Th2 and anti-inflammatory cytokines, such as IL-10 and GM-CSF. ...
Taxane-Based Breast Cancer Treatment Cost-Effective Compared to 5 ... Dec 13, 2005
DG News ..."Most clinicians, in order to prevent bouts of febrile neutropenia would add GM-CSF [granulocyte monocyte colony stimulating factor]," she said. ...
ASH: Rituxan-Vaccine Combo Boosts NHL Response Rates Dec 13, 2005
MedPage Today, ...then went on to receive the FavId vaccinations in a dose of 1 mg delivered subcutaneously monthly for six months, starting on week 12, with GM-CSF at 250 mcg ...
Cell Genesys Reports Positive Results from Phase 2 Trial of GVAX ... Dec 12, 2005
DG News The vaccines are comprised of tumor cells that have been genetically modified to secrete GM-CSF, an immune stimulatory hormone that plays a key role in ...
Biotechs find themselves more coveted Jan 15, 2006
Philadelphia Inquirer, ...developing together. The acquisition was the third major purchase for Amgen since 2002, when it paid $11 billion to buy Immunex Corp. and ...
News For Your Web Site Jan 9, 2006
dBusinessNews Seattle (press release), Dr. Gillis, a biotech pioneer, co-founded both Immunex and Corixa and served as chairman and chief executive officer of both companies. ...
Seattle biotech strikes deal with drug giant Jan 4, 2006
Seattle Post Intelligencer Founded in 2002 by former executives of Chiron, Immunex and Xcyte Therapies, Trubion employs just 40 people at its downtown Seattle headquarters. ...
Trubion Starts New Year With Potential $840M Wyeth Deal Jan 3, 2006
BioWorld Online (subscription), Enbrel was first developed at Immunex Corp., of Seattle, in collaboration with American Home Products. Immunex later merged with ...
Wyeth, Trubion target arthritis, cancer Jan 3, 2006
Reuters He noted that several top executives of Trubion once worked at Immunex, the US biotech company that developed Enbrel with Wyeth, which was then called American ...
Amgen Buys Abgenix for $2.2B Dec 16, 2005
Red Herring, The two companies have been partnering on developing a cancer treatment known as panitumumab since 2002, when Amgen acquired Immunex. ...
Amgen Buys a Potential Blockbuster Dec 15, 2005
BusinessWeek ..."A WONDERFUL ACHIEVEMENT." As one analyst in the post-deal call pointed out, when Amgen bought Immunex in 2002 for $10 billion, it predicted that Immunex's ...
Amgen to Buy Abgenix, Getting Complete Control of New Colon Cancer ... Dec 14, 2005
New York Times, In 2002, it paid about $10 billion for Immunex to obtain the big-selling rheumatoid arthritis drug, Enbrel. The Immunex acquisition ...
Amgen to Acquire Abgenix for $2.2 Billion in Cash (Update3) Dec 14, 2005
Bloomberg The acquisition would be Amgen's biggest since it bought Immunex in 2002 for $8.8 billion, gaining the rheumatoid arthritis drug Enbrel. ...
Abgenix German Shares Jump on Amgen's $2.2 Billion Cash Offer Dec 15, 2005
Bloomberg It would be Amgen's biggest transaction since the company bought Immunex in 2002 for $8.8 billion, gaining the rheumatoid arthritis drug Enbrel. ...
Ex-Dendreon exec joins VLST Corp. Jan 6, 2006
Seattle Post Intelligencer ...executive chairman. Gillis, co-founder of Immunex and Corixa, is a partner in the Seattle office of ARCH Venture Partners. Simonetti's ...
Simonetti, Gillis join VLST Jan 6, 2006
Seattle Post Intelligencer ...executive chairman. Gillis, co-founder of Immunex and Corixa, is a new partner in the Seattle office of Arch Venture Partners. Arch ...
Biotech behemoth beefs up Dec 15, 2005
Los Angeles Daily News, After buying Immunex in 2002, Thousand Oaks-based Amgen began working closely with Abgenix on a development and commercialization strategy for panitumumab. ...
Amgen to acquire Abgenix for $2.2bn Dec 15, 2005
New Ratings The acquisition marks the largest one since Amgen took over Immunex in 2002 for $8.8 billion to gain the rheumatoid arthritis drug Enbrel. ...
Amgen seals deal to buy Abgenix for $2.2 billion Dec 15, 2005
9NEWS.com, ...a drug for colon, head and neck cancers the companies have been developing jointly since 2002 under an agreement Amgen assumed with its purchase of Immunex. ...
Amgen to Buy Drug Firm Dec 15, 2005
Los Angeles Times, The acquisition confirms Amgen's enthusiasm for Panitumumab, a drug that came to Amgen as a result of its 2002 purchase of Immunex Corp., Abgenix's original ...
Amgen to acquire biotech working on cancer drugs Dec 15, 2005
Seattle Times, ...are developing. Abgenix had earlier sold half the drug's future profits to Seattle's Immunex, which Amgen acquired in 2002. Amgen ...
Amgen to acquire Abgenix for $2.2 billion Dec 15, 2005
San Jose Mercury News, The drug would have been Abgenix's first commercial product. Abgenix had been developing panitumumab with Immunex, which Amgen acquired in 2002. ...
Psoriasis Drug May Also Clear Up Depression and Fatigue Dec 15, 2005
CNN ...patients with psoriasis with high levels of depression and fatigue," they said. The study was funded by Immunex, which markets Enbrel.
Amgen Offers To Buy Out Abgenix For $2.2B In Cash Dec 14, 2005
BioWorld Online (subscription), ...a monoclonal antibody for colorectal cancer partnered with Amgen, which began working with Abgenix on the compound after acquiring Immunex Corp., of Seattle ...
Amgen to buy Abgenix Dec 14, 2005
Providence Journal (subscription), Abgenix had earlier sold half the drug's future profits to Immunex Corp., which Amgen acquired in 2002. Abgenix is also developing an osteoporosis drug. ...
Amgen to purchase Abgenix Dec 15, 2005
Contra Costa Times, Amgen's partnership with Abgenix began in 2002, when the Thousand Oaks-based company took over co-development of panitumumab from Immunex Corp. ...
Amgen to Acquire Abgenix for $22.50 Per Share; Provides Amgen With ... Dec 14, 2005
Finanzen.net, ...panitumumab.Working closely with Abgenix under a co-development agreement thatAmgen assumed as a result of its acquisition of Immunex Corporation in2002, Amgen ...
Psoriasis drug may also cut depression: study Dec 14, 2005
Herald News Daily, Enbrel was originally discovered by Immunex, now part of Amgen, and jointly developed with Wyeth, which markets the product outside North America.
Berlex Oncology Introduces New Formulation of Leukine(R) With ... Jan 10, 2006
PR Newswire (press release), ...affiliate of Schering AG, Germany (NYSE: SHR, FSE: SCH), today announced its granulocyte macrophage colony stimulating factor (GM-CSF) LEUKINE(R) (sargramostim ...
Berlex Oncology Introduces New Formulation of Leukine With ... Jan 10, 2006
PharmaLive.com (press release), Laboratories, a US affiliate of Schering AG, Germany , today announced its granulocyte macrophage colony stimulating factor (GM-CSF) LEUKINE(R) (sargramostim ...
(PRN) - Berlex Oncology Introduces New Formulation of Leukine(R) ... Jan 10, 2006
Bolsamania.com, ...(PRN) - Maxwell Technologies Expands Worldwide Distributor Network to Serve Increasing Demand for BOOSTCAP(R) Ultracapacitor Products ... [+. ...
Rituxan® Plus GM-CSF Safe and Effective for Chronic Lymphocytic ... Jan 13, 2006
Cancer Consultants (press release), Cancer Center have reported that the combination of Rituxan® (rituximab) and granulocyte macrophage-colony stimulating factor (Leukine®, sargramostim) is ...
Rituxan® Plus GM-CSF Safe and Effective for Chronic Lymphocytic ... Jan 12, 2006
Cancer Consultants (press release), Cancer Center have reported that the combination of Rituxan (rituximab) and granulocyte macrophage-colony stimulating factor, Leukine®, (sargramostim) is well ...
Flying with the leader Jan 1, 2006
Bothell Herald, The plant, in the Opus Northpointe Corporate Campus off 164th Street SW, will produce Leukine, which fights infections in cancer patients and is being tested ...
|
|
|
